  |
           
|
     |
  |
  |
Click the following to see the respective articles: National Jewish Medical and Research Center Gets a New Name and Forges Toward the Future CHAD Therapeutics Finds New Home in Naples, Florida
National Jewish Medical and Research Center Gets a New Name and Forges Toward the Future US News & World Report, in its July 2008 Issue, has named National Jewish Medical and Research Center the best hospital in the nation for respiratory care for the 11th consecutive year As part of the ranking, board-certified pulmonologists around the country mentioned National Jewish more often than any other hospital when asked to name the best respiratory hospitals in the nation. In addition to recognition by pulmonologists, the hospital rankings were based upon various care-related factors, such as nursing and patient services. National Jewish has world-renowned programs in respiratory, cardiac and immune disorders including asthma, chronic obstructive pulmonary disease, lupus and other rheumatologic diseases, coronary artery disease, lung cancer, and allergies. As well as this number one ranking, the center now has a new name, National Jewish Health. Everything Respiratory spoke with Michael Salem, MD, the CEO and President of National Jewish Health, to find out how National Jewish Health is improving and moving forward. Dr. Salem, how did the name change come about and why? What we’re trying to do in terms of organizational strategy is to go forward. For many, many years National Jewish Health has been the top ranked respiratory hospital in the country with a long heritage taking care of patients in an amazing way. National Jewish Health has always done great research and been a leader in educating the next generation of doctors and scientists. Our board recognized that we wanted to continue to lead going forward as we’ve always had a tremendously innovative culture. Second, patients use to come out to Denver when they only had the air and altitude to try to cure patients of tuberculosis. Before antibiotics were used, it would mean doing surgery and in this respect many of the doctors and scientists were hired with innovative thinking. So relative to that we understand that medicine is always changing and we didn’t think we could do the same things for the same way for the next 10 years and expect to continue to lead. 18 months ago we came forward with a new strategy for the organization that basically stated that we were going to take advantage of these changes by being typically reactive. For example you have an allergic disease or lung cancer or you cough and only then do you decide to go to the doctor. What we want to do is to bring our research and clinical efforts together. We want to take advantage of the whole revolution in genetics and proteomics (the study of proteins associated with diseases) and other areas to implement them practically, whether it is early diagnosis or whether it be predictive genetic testing. These can be done by bringing the research and clinical together. Whether it is advanced diagnostics, molecular labs bringing forward targeted treatments, or even our geographic strategy, we’ve been developing this healthcare network that basically means an expansion of our capabilities at our locations in order to serve more people. We really think that we’re developing this network that better reflects this strategy. And third, we wanted a descriptor for the institution that really reflected what we’re trying to do. While we take care of basic patient education we have so many other things to offer as well. One is our idea of having a kindergarten through eighth grade school on campus for chronically ill kids, The Kunsberg School. I don’t know of any other medical center that does that, to invest millions of dollars a year in investing in our kids. And similarly we have programs on campus to address behavior associated preventable death in the U.S., an example being our smoking cessation program and our weight management program that we do for hundreds of thousands of people around the country. We take care of these Quit Lines for six states where you’re actually calling National Jewish Health and getting telephonic advice, guidance, internet platforms, etc and we’ve extended that now to weight management. So we want to reflect this concept of what the essence is of National Jewish Health, which we believe is a science and discovery based organization. It’s a transformative experience to come here, this being a unique health care experience by bringing science together in terms of new discoveries. And then we’re about the quality of people’s lives. We think this notion of personalized medicine or personalized health, that’s what it’s all about. So our promise going forward is science transforming life which we think describes the institution, and changing the name to National Jewish Health from Research Center, we think really fits what we’re trying to achieve going forward. Aside from the current rankings in such prestigious magazines, how does National Jewish Health spread the word around about what advantages are to be found there? We have a number of offices around the country that help get the word out but we don’t have any place other than Colorado where we deliver clinical care and 35% of our patients come from out of state which is how we continue to build a national brand for National Jewish Health. Why does National Jewish Health receive such accolades and recognition? Bottom line, it’s because of the people here. Dr. Salem, what’s your background and how does that improve National Jewish Health? I’m a general surgeon and a critical care doctor. I spent a lot of years in academic medicine at places like George Washington University, Johns Hopkins, and Massachusetts General. I did that for many years and then helped start a health care company that was basically devoted to commercializing discoveries from academic researchers. Since I had both academic and business experience, I decided to use my experience to move National Jewish Health forward and the bottom line is that we have adopted a new name and logo to better communicate our commitment to leading the evolution of healthcare from reactive trial-and-error medicine to proactive, personalized health. To learn more about the services and opportunities available at National Jewish Health, contact them at: National Jewish Health Or view their website at www.nationaljewish.org
CHAD Therapeutics Finds New Home in Naples, Florida Naples, Florida. (July 24, 2008). Inovo Inc. announced today that it has completed its relocation of CHAD Therapeutics’ production and sales and marketing functions from California to Naples, Florida. Inovo acquired CHAD in February of this year. CHAD Therapeutics has been the leading innovator in the field of oxygen conservation since the introduction of the first conserving device in 1983. Today, CHAD offers the broadest line of electronic, pneumatic and disposable conservers on the market, and is uniquely positioned to meet the needs and preferences of a wide range of oxygen patients. Inovo has been a leading manufacturer of both regulators and conservers for the private-label market for over 10 years. “The combination of CHAD’s leadership position and Inovo’s manufacturing expertise will allow CHAD to continue in the tradition of innovation and excellence,” explains George Harris, CEO of Inovo, Inc. In fact, Harris suggests that Inovo’s engineering experience and advanced machining technology will strengthen the CHAD brand. “Inovo’s proven track record for success is directly related to our specialization in the niche market of oxygen conservation. This focus enables us to stay at the forefront of technology, and will ensure the continual evolution and improvement of CHAD’s product line.” Another benefit of Inovo’s specialization is the speed at which the Company can help CHAD customers respond to what has become an extremely dynamic marketplace. “With 100% of our time and energy devoted to oxygen conservation, we are able to focus on this segment of the industry, identify needed improvements, and deliver technological advancements quickly and efficiently,” says Harris. “This gives us a unique competitive advantage.” Faced with rising delivery costs and cuts in oxygen reimbursement, home medical equipment providers are dependent upon the ability to respond quickly and effectively to changing market conditions. “We obviously have a vested interest in their success,” states Harris, “so it is imperative that our business objectives are aligned with their needs.” Harris concludes, “We look forward to building upon CHAD’s reputation for quality and innovation. We share the same dedication to excellence and superior customer service and we want to assure CHAD customers that our ultimate goal is to exceed their expectations.” About Inovo, Inc. Founded in 1997, Inovo, Inc. quickly became a leading manufacturer of oxygen regulators and conservers for the private-label market. The Company’s products are sold through a national network of distributors servicing the home healthcare, EMS and hospital industries. Inovo closed on the sale of CHAD Therapeutics’ oxygen conserving assets in February of 2008, and completed the relocation of CHAD’s manufacturing, sales and marketing functions to its Naples headquarters in June of this year. Inovo retains the right to market and sell under the name of CHAD Therapeutics. CHAD Therapeutics is now located at 2975 Horseshoe Drive South, Suite 600, Naples, FL 34104. You can reach the Company by calling 800-423-8870, or visiting www.chadtherapeutics.com. The following is from a post to the COPD-ALERT Yahoo group: June 11, 2008 Dear AANMA Friends and MDI Transition Working Group Members: Please take a moment to ask your Congressional Representatives to sign on to the Dear Colleague letter to Secretary Leavitt regarding the MDI Transition! During Asthma Awareness Day Capitol Hill (AADCH) May 7, 2008, we asked Congress to help make millions of respiratory patients aware that they must switch from CFC propelled albuterol inhalers to non-CFC alternatives by December 31, 2008. The federal mandate did not come with provisions necessary to inform or monitor patients making the transition. Nor did it compensate families and patients who must now assume the financial burden of making the switch. Representatives Nita Lowey ((D-NY) and Cliff Stearns (R-FL) took the lead and are circulating a Dear Colleague letter on the Hill asking other offices to sign onto a letter to HHS Secretary Leavitt asking him to (1) launch a national awareness and education campaign, (2) institute a process for monitoring patients, and (3) place HFA inhalers at the lowest co-pay tier for Medicare patients. Please take a moment to ask your Congressional Representatives to sign on to letter to Secretary Leavitt! To locate your Congressional Representative¹s phone number, click here http://www.capwiz.com/aanma/home/ and enter in your zip code. Immediately place a call to your Representative. Ask to speak with the Health Legislative Assistant. Identify yourself and where you are from and say that you hope the Representative will sign onto the Dear Colleague letter to HHS Secretary Leavitt by contacting on the Democratic side Representative Nita Lowey¹s office at 202-225-6506 (ask for Jean Doyle) or on the Republican side Representative Stearns¹ office at 202-225-5744 (ask for Mike Anway) by this Friday, June 13, 2008. If you are connected to voice mail, leave a message with the above information. Please take one extra moment to let me know you made the call: Thank you for your continuing support and immediate response to issues that affect patients with respiratory conditions. Sandra Sandra J. Fusco-Walker *If you are represented by Congresswoman Nita Lowey or Congressman Cliff Stearns any of the following Members who have already signed on, please also call and thank them for their support. Rep. Tammy Baldwin ((D-WI) 202-225-2906
|
||
 |
 |
Mission | Articles | Subscribe | Contact Us | Advertise With Us | Advertisers | Home
©2006-2008 Everything Respiratory • 2591
B-3/4 Road • Grand
Junction, CO 81503 • ph. 877-ERMAG4U (877-376-2448) • 970.257.1866 • fx. 970-257-7733
For more information on our Terms and
Conditions and Privacy
Policy.
All
artwork and photos are copyrighted. Website Design by Merge
2 Media.